Ovolux™ Brand Eggshell Membrane Reduces the Clinical Signs of Aging by Improving Skin, Hair & Fingernail Appearance, Texture, and Biomechanical Properties: A Single Center, Randomized, Double Blind, Placebo Controlled Clinical Trial  

作　　者：Kevin J. Ruff Nena Dockery Cem Aydogan Mathew Back Kevin J. Ruff;Nena Dockery;Cem Aydogan;Mathew Back(ESM Technologies, LLC, Carthage, USA;Phytonet AG, Schindellegi, Switzerland)

机构地区：[1]ESM Technologies, LLC, Carthage, USA [2]Phytonet AG, Schindellegi, Switzerland

出　　处：《Journal of Cosmetics, Dermatological Sciences and Applications》2024年第4期306-322,共17页化妆品、皮肤病及应用期刊(英文)

摘　　要：Background: As the population of people aged 65 and older increases, greater attention is being paid to issues surrounding skin aging. This study was conducted to evaluate the efficacy of an oral unhydrolyzed eggshell membrane (ESM) ingredient (branded Ovolux™) versus placebo on both objective and subjective markers of skin aging in middle-aged and senior adults, and also to assess the possible benefits of Ovolux™ on the health of hair and fingernails. Methods: Sixty-three healthy, men and women (aged 35 - 66) were randomly assigned to receive either oral ESM 300 mg (n = 32) or placebo (n = 31) once daily for 12 weeks. The primary endpoint was any statistically significant improvement in skin elasticity in the anterior region of the temporal fossa of the face versus placebo evaluated at 12 weeks of treatment based upon measurements taken with the Cutometer® MPA 580 multi-probe system. Secondary endpoints were improvement in skin firmness, viscoelasticity, hydration, or trans-epidermal water loss versus placebo. Additional secondary endpoints were any improvement in skin, hair, or fingernail subjective parameters versus placebo as determined via Patient’s Assessments. Results: Supplementation with Ovolux™ ESM produced a significant absolute treatment effect (TEabs) versus placebo after both six weeks (TEabs +8.4%, p = 0.019) and twelve weeks of treatment (TEabs +12.2%, p = 0.002) for the primary outcome measure total elasticity (R2). There were also significant treatment responses versus placebo for the objective measures of firmness (R0), net elasticity (R5), and viscoelasticity (R6) at both timepoints (R0: Week 6, −23.9%;Week 12, −16.8%) (R5: Week 6, +9.5%;Week 12, +10.6%) (R6: Week 6, −17.9%;Week 12, −17.7%), as well as for skin hydration versus placebo at both 6 weeks (+8.3%) and 12 weeks (+8.6%) of treatment. There were also significant improvements in the ESM treatment group versus placebo in the subjective measures of skin appearance, skin texture, overall skin health, hair texture, and oveBackground: As the population of people aged 65 and older increases, greater attention is being paid to issues surrounding skin aging. This study was conducted to evaluate the efficacy of an oral unhydrolyzed eggshell membrane (ESM) ingredient (branded Ovolux™) versus placebo on both objective and subjective markers of skin aging in middle-aged and senior adults, and also to assess the possible benefits of Ovolux™ on the health of hair and fingernails. Methods: Sixty-three healthy, men and women (aged 35 - 66) were randomly assigned to receive either oral ESM 300 mg (n = 32) or placebo (n = 31) once daily for 12 weeks. The primary endpoint was any statistically significant improvement in skin elasticity in the anterior region of the temporal fossa of the face versus placebo evaluated at 12 weeks of treatment based upon measurements taken with the Cutometer® MPA 580 multi-probe system. Secondary endpoints were improvement in skin firmness, viscoelasticity, hydration, or trans-epidermal water loss versus placebo. Additional secondary endpoints were any improvement in skin, hair, or fingernail subjective parameters versus placebo as determined via Patient’s Assessments. Results: Supplementation with Ovolux™ ESM produced a significant absolute treatment effect (TEabs) versus placebo after both six weeks (TEabs +8.4%, p = 0.019) and twelve weeks of treatment (TEabs +12.2%, p = 0.002) for the primary outcome measure total elasticity (R2). There were also significant treatment responses versus placebo for the objective measures of firmness (R0), net elasticity (R5), and viscoelasticity (R6) at both timepoints (R0: Week 6, −23.9%;Week 12, −16.8%) (R5: Week 6, +9.5%;Week 12, +10.6%) (R6: Week 6, −17.9%;Week 12, −17.7%), as well as for skin hydration versus placebo at both 6 weeks (+8.3%) and 12 weeks (+8.6%) of treatment. There were also significant improvements in the ESM treatment group versus placebo in the subjective measures of skin appearance, skin texture, overall skin health, hair texture, and ove

关 键 词：Eggshell Membrane Skin Aging Elastosis LAXITY 

分 类 号：TN9[电子电信—信息与通信工程]